JD Supra

Federal Court upholds validity of patent relating to paliperidone palmitate

On August 23, 2022, the Federal Court issued its public judgment and reasons in two actions under subsection 6(1) of the Patented Medicines (Notice of Compliance) Regulations (the “Regulations”) ...
FiercePharma

Teva, Viatris revive patent challenge on J&J's long-acting schizophrenia blockbuster Invega Sustenna

After incurring a loss in New Jersey federal court in 2021, Teva and Viatris have successfully resurrected challenges to the last remaining U.S. patent on a lucrative Johnson & Johnson schizophrenia ...
JD Supra

Federal Court of Appeal affirms paliperidone palmitate claims are not unpatentable methods of medical treatment

In a 2022 decision involving Janssen and Pharmascience, the Federal Court found that the claims of Canadian Patent No. 2,655,335 (335 patent, relating to paliperidone palmitate (Janssen’s INVEGA ...
Medscape

Onset of Efficacy and Tolerability Following the Initiation Dosing of Long-acting Paliperidone Palmitate

With respect to tolerability concerns with the recommended paliperidone palmitate initiation dosing, this study did not reveal unexpected adverse events or high rates of specific adverse events in the ...